Adjudicated KR KRX
Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation
Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.
CASE PROFILE & BENCHMARKS
- Target Issuer: Samsung BioLogics Co., Ltd. (KR).
- Fraud Period: January 1, 2018 to December 31, 2020.
- Reported Overstatement: $3.8B.
- Total Fines & Penalties: $7.0M.
- Maximum Incarceration: No prison sentence.
- Independent Auditor: Samjong KPMG.
- Primary Schemes: acquisition accounting abuse.
- Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $3.8B USD reported
TOTAL PENALTIES $7.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2020 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR Financial Supervisory Service (South Korea) KR
FORENSIC ACCOUNTING AUTOPSY & MECHANICS
HOW IT WAS DONE| Forensic Aspect | Regulatory Record & Ledger Mechanics |
|---|---|
| Accounting Mechanics | In settled proceedings with admissions, the regulator found that The company manipulated its accounting records by executing schemes under acquisition-accounting-abuse. Financial reports filed with market regulators contained material misstatements that distorted true financial condition. |
| Evidentiary Finding | Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit. |
| Mechanism Definition | Manipulating purchase price allocation in mergers to write down acquired assets and create artificial liability reserves that can later be reversed into earnings. |
| Affected Accounts | Goodwill (Asset) • Acquired Tangible Assets & Receivables (Asset) • Assumed Liabilities & Restructuring Reserves |
| Issuer Corporate Context | South Korean contract drug maker that changed the accounting treatment of an affiliate, inflating net profit by 4.5 trillion won prior to IPO. |
| Independent Auditor | Samjong KPMG : South Korean member firm of KPMG involved in valuation of Samsung BioLogics affiliates. |
| Primary Discovery Method | Regulatory Enforcement & Forensic Audit |
ILLUSTRATIVE GENERAL LEDGER MECHANICS (ACQUISITION ACCOUNTING ABUSE AND CUSHION CREATION)
IMPROPER VS. GAAP/IFRS TREATMENT| Improper Booked Entry | Proper GAAP / IFRS Treatment | Accounting Distortion & Mechanism |
|---|---|---|
| DR: Goodwill (inflated): $150,000,000 CR: Excess Pre-Acquisition Liabilities Accrued: $100,000,000 | DR: Under ASC 805, acquired assets and liabilities must be recognized at true fair value on acquisition date CR: No arbitrary cushion reserves that distort post-merger profitability | Undervaluing acquired inventory and writing down acquired equipment to minimums, then selling the inventory at high margins in subsequent quarters to show 'synergies.' |
FINANCIAL STATEMENT & RATIO DISTORTIONS
QUANTITATIVE SCREENING SIGNALS| Financial Metric / Ratio | Distortion Direction | Forensic Explanation |
|---|---|---|
| Goodwill to Total Assets | Increases rapidly | Purchase price overages are loaded onto non-depreciable goodwill. |
| Taxonomy | Applicable Scheme Classifications |
|---|---|
| Correlated Schemes |
CHARGED RESPONDENTS & OUTCOMES
1 NAMED PARTIES| Respondent | Role | Disposition & Judicial Outcome | Prison | Civil Penalty | O&D Bar |
|---|---|---|---|---|---|
| Samsung BioLogics Co., Ltd. | ISSUER | Enforcement order and financial sanctions imposed. | None | $7.0M | No |
RED FLAGS OBSERVED PRIOR TO DISCOVERY
1 EARLY WARNING INDICATORS| Red Flag Indicator | Period Observed | Observed Forensic Anomaly | Diagnostic View |
|---|---|---|---|
| CASH FLOW TO NET INCOME DIVERGENCE | 2018 | Operating cash flow severely diverged from reported earnings | Inspect Metric → |
ENFORCEMENT ACTIONS & PRIMARY DOCKETS
PRIMARY SOURCE CITATIONS| Filing Date | Type & Docket ID | Enforcement Order & Regulatory Findings | Disposition | Primary Record |
|---|---|---|---|---|
| September 20, 2020 | foreign regulator ENF-2018-samsung-biologics | Enforcement Action: Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit. Securities & Corporate Law Compliance | admitted | Docket Record ↗ |
TIMELINE OF EVENTS
2 CHRONOLOGICAL MILESTONES| Date | Event Category | Chronological Forensic Milestone |
|---|---|---|
| June 1, 2018 | MISSTATEMENT | Material accounting irregularities commenced. |
| September 20, 2020 | ENFORCEMENT | Regulators commenced formal proceedings. |